Although rare, checkpoint inhibitor–associated autoimmune diabetes mellitus (CIADM) and adrenal insufficiency have been increasingly associated with anti-PD-1/PD-L1 therapies. This evidence concerns the gene PDCD1 and Adrenal insufficiency.